Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance
Clinica Chimica Acta · 2026-03 · 584 · 120874
DOI: 10.1016/j.cca.2026.120874 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinica Chimica Acta, 2026-03. Verfasst von Ye Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Translational Medicine of Traditional Chinese Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 2…. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Tumor Microenvironment, Biomarkers, Tumor, Neovascularization, Pathologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 109 Literaturangaben. Gefördert von: Heilongjiang University of Chinese Medicine.
Abstract (Originalsprache)
Ovarian cancer remains one of the most lethal gynecologic malignancies, largely because of late-stage diagnosis, extensive intratumoral heterogeneity, and the dynamic complexity of the tumor microenvironment (TME). Emerging evidence highlights the TME as a central orchestrator of immune evasion, angiogenic remodeling, and therapeutic resistance, which are three mechanistic pillars that critically shape disease progression and treatment outcomes. This narrative review synthesizes current mechanistic insights into how stromal, immune, and vascular components interact to promote tumor survival and metastasis. We examine the roles of immunosuppressive cell populations, cytokine networks, and checkpoint pathways in facilitating immune escape; delineate angiogenic drivers and endothelial-tumor crosstalk that sustain aberrant vascularization; and explore TME-mediated mechanisms that underlie chemoresistance, targeted therapy failure, and limited immunotherapy responsiveness. Furthermore, we evaluate recent advances in biomarker discovery, including the identification of circulating ncRNAs, exosomal signatures, spatial immune profiles, and TME-derived molecular indicators, which hold promise for improving early detection, prognostication, and therapeutic stratification. By integrating mechanistic biology with translational biomarker innovation, this review outlines a forward-looking framework for leveraging TME-informed diagnostics and therapeutics to enhance precision oncology in ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Center for Translational Medicine of Traditional Chinese Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 26 Heping Road, Harbin 150040, Heilongjiang, China.
- Department of Oncology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 26 Heping Road, Harbin 150040, Heilongjiang, China.
- Graduate School of Heilongjiang University of Chinese Medicine, 24 Heping Road, Harbin 150040, Heilongjiang, China.
- Department of Gynecology, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, 26 Heping Road, Harbin 150040, Heilongjiang, China. Electronic address: doctorfengmen@163.com.
Förderung
- Heilongjiang University of Chinese Medicine
Zitieren
APA
Liu, Y., Zhang, L., Wang, Q., Li, X., & Feng, X. (2026). Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance. Clinica Chimica Acta, 584, 120874. https://doi.org/10.1016/j.cca.2026.120874
Vancouver
Liu Y, Zhang L, Wang Q, Li X, Feng X. Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance. Clinica Chimica Acta. 2026;584:120874. doi:10.1016/j.cca.2026.120874
BibTeX
@article{Liu2026,
author = {Liu, Ye and Zhang, Lijia and Wang, Qian and Li, Xinyue and Feng, Xiaoling},
title = {Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance},
journal = {Clinica Chimica Acta},
year = {2026},
volume = {584},
pages = {120874},
doi = {10.1016/j.cca.2026.120874}
}
EUVIMED